Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Introduction: Because of environmental concerns, the use of chlorofluorocarbons in pressurised metered dose inhalers (pMDI) is being phased out. Innovata Biomed Ltd has developed an alternative device, the Clickhaler®, which is a multiple-dose dry powder inhaler (DPI). The present study compared patient acceptability of the salbutamol Clickhaler® with a prestudy device. Patients and Methods: Adult patients with asthma who were receiving bronchodilator therapy (either salbutamol pMDI or terbutaline Turbuhaler® DPI) were entered into this open-label study, which was designed to assess the acceptability of the salbutamol Clickhaler® before and after a 4-week period of routine clinical use. Results: Overall acceptability questions showed that 99% of patients found the new DPI very easy/easy to use at visit 1 and 94% at visit 2. At the same two visits, the salbutamol Clickhaler® was rated very good/good overall by 98 and 80% of the patients, respectively. The number of patients finding the salbutamol Clickhaler® easier to use (44%) was statistically significantly higher (p < 0.05) than the number who found their prestudy inhaler easier to use (27%). Conclusion: This study demonstrated that the salbutamol Clickhaler® showed a high degree of acceptability and ease of use when used routinely by adult patients with asthma.

Original publication




Journal article


Clinical Drug Investigation

Publication Date





195 - 199